Breaking News Instant updates and real-time market news.

AVXS

AveXis

$115.91

-3.69 (-3.09%)

, NVS

Novartis

$80.20

-0.86 (-1.06%)

09:04
04/09/18
04/09
09:04
04/09/18
09:04

On The Fly: Pre-market Movers

HIGHER: AveXis (AVXS), up 82% after announcing an agreement to be acquired by Novartis (NVS) for $218 per share, or $8.7B in cash. Novartis shares are up about 1% in pre-market trading following the announcement... Therapix Biosciences (TRPX), up 33% after Phase 2 results of THX-110 showed improved symptoms over time in adult subjects with Tourette syndrome... Merck (MRK), up 2.5% after the Phase 3 KEYNOTE-042 trial evaluating Keytruda as monotherapy for the first-line treatment of locally advanced or metastatic non-small cell lung cancer met its primary endpoint of overall survival... Regenxbio (RGNX), up 25% after Novartis' deal to buy AveXis. Jefferies analyst Michael Yee identified Regenxbio as another "mid-late stage gene therapy player" on list on which he also named Bluebird Bio (BLUE), Spark Therapeutics (ONCE), BioMarin (BMRN), Abeona Therapeutics (ABEO), Regenxbio (RGNX), Nightstar Therapeutics (NITE) and Voyager Therapeutics (VYGR). LOWER: Menlo Therapeutics (MNLO), down 65% after the company reported that the Phase 2 trial of serlopitant for the treatment of pruritus missed its primary and key secondary endpoints... Shares of mortgage insurers MGIC Investment (MTG), Radian Group (RDN) and Essent Group (ESNT) are all sliding in pre-market trading after MGIC announced earlier reduced borrower-paid premium rates that reflect the lower corporate tax rate signed into law in 2017. Borrower-paid mortgage insurance premium rates on the most popular premium plans have been reduced by an average of approximately 11%, said MGIC.

AVXS

AveXis

$115.91

-3.69 (-3.09%)

NVS

Novartis

$80.20

-0.86 (-1.06%)

RGNX

Regenxbio

$27.20

-1.1 (-3.89%)

MRK

Merck

$53.36

-1.17 (-2.15%)

MNLO

Menlo Therapeutics

$35.22

-1 (-2.76%)

TRPX

Therapix Biosciences

$5.20

-0.3912 (-7.00%)

BLUE

Bluebird Bio

$162.70

-7.45 (-4.38%)

ONCE

Spark Therapeutics

$62.06

-1.19 (-1.88%)

BMRN

BioMarin

$76.01

-2.69 (-3.42%)

ABEO

Abeona Therapeutics

$14.00

-0.35 (-2.44%)

NITE

Nightstar Therapeutics

$11.70

-0.19 (-1.60%)

VYGR

Voyager Therapeutics

$17.37

-0.76 (-4.19%)

MTG

MGIC Investment

$12.82

-0.17 (-1.31%)

RDN

Radian Group

$19.14

-0.2 (-1.03%)

ESNT

Essent Group

$42.07

-0.82 (-1.91%)

  • 09

    Apr

  • 14

    Apr

  • 16

    Apr

  • 18

    Apr

  • 23

    Apr

  • 24

    Apr

  • 01

    May

  • 08

    May

  • 17

    May

  • 25

    May

  • 12

    Sep

  • 23

    Oct

AVXS AveXis
$115.91

-3.69 (-3.09%)

04/09/18
MZHO
04/09/18
DOWNGRADE
MZHO
Neutral
AveXis downgraded to Neutral from Buy at Mizuho
Mizuho downgraded AveXis (AVXS) to Neutral following the acquisition by Novartis (NVS) for $218 per share in cash.
04/09/18
BERN
04/09/18
NO CHANGE
Target $144
BERN
Outperform
Bernstein not too surprised with AveXis sale
Bernstein analyst Vincent Chen notes that Novartis (NVS) and AveXis (AVXS) announced an agreement for the former to purchase AveXis for $218 per share, a total of $8.7B. The analyst says he has long suspected he would see acquisitions in gene therapy and that AveXis could be a prime candidate, so he is not too surprised to see it go. However, the analyst acknowledges that he had not pegged Novartis as the top contender. Noting that the announcement should be a positive for others in the space, Chen reiterates an Outperform rating and $144 price target on AveXis shares.
04/09/18
JEFF
04/09/18
NO CHANGE
JEFF
Buy
Jefferies ponders other potential suitors for AveXis after Novartis deal
Jefferies analyst Biren Amin asks who else can jump into the mix after AveXis (AVXS) agreed to be acquired by Novartis (NVS) for $218 per share in an all-cash deal. The analyst, who does not expect anti-trust issues to arise with the deal on the table, notes the speculation that Biogen (BIIB) may need to evaluate AveXis at some point. The Novartis deal could be the "trigger that forces it to do so," Amin writes in a research note. Further, the analyst has always felt Roche (RHHBY) could have an interest in AveXis given its development program with RG7916. He points out that AveXis Chairman Dan Welch was the CEO of Intermune when Roche purchased the company in 2014 for $8.3B. AveXis in premarket trading is up 81%, or $94.14, to $210.05.
04/09/18
JEFF
04/09/18
NO CHANGE
JEFF
Jefferies highlights other gene theraphy players after AveXis takeover
Novartis' (NVS) deal to acquire AveXis (AVXS) for $8.7B should remind investors about the ongoing attractiveness within smid-cap biotech, Jefferies analyst Michael Yee tells investors in a research note. Novartis' two large gene therapy deals in four months will lead to a question of "who's next," the analyst adds. Yee says other mid-late stage gene therapy players include Bluebird Bio (BLUE), Spark Therapeutics (ONCE), BioMarin (BMRN), Abeona Therapeutics (ABEO), Regenxbio (RGNX), Nightstar Therapeutics (NITE) and Voyager Therapeutics (VYGR).
NVS Novartis
$80.20

-0.86 (-1.06%)

03/21/18
WELS
03/21/18
NO CHANGE
WELS
Outperform
Amphastar court win a 'major' positive, says Wells Fargo
Wells Fargo analyst David Maris called the news of Massachusetts' District Court entering a final judgement in favor of Amphastar (AMPH) in the patent lawsuit regarding Lovenox brought by Momenta (MNTA) and Novartis' (NVS) Sandoz division a "major positive" that again demonstrates Amphastar's ability to face down larger, better-funded companies and get difficult products to market. He maintains an Outperform rating on Amphastar shares.
RGNX Regenxbio
$27.20

-1.1 (-3.89%)

03/12/18
EVER
03/12/18
DOWNGRADE
EVER
In Line
Regenxbio downgraded to In Line from Outperform at Evercore ISI
03/12/18
EVER
03/12/18
DOWNGRADE
Target $35
EVER
In Line
Regenxbio downgraded to In Line on valuation at Evercore ISI
As previously reported, Evercore ISI downgraded Regenxbio to In Line from Outperform and raised its price target to $35 from $30. Analyst Josh Schimmer cites the strong run in shares and notes value of the company will depend heavily on Regenxbio's ability to successfully develop and commercialize its own compelling gene therapy products.
02/12/18
MZHO
02/12/18
INITIATION
MZHO
Neutral
Regenxbio initiated with a Neutral at Mizuho
Mizuho analyst Difei Yang started Regenxbio with a Neutral rating and $28 price target.
MRK Merck
$53.36

-1.17 (-2.15%)

04/09/18
HCWC
04/09/18
NO CHANGE
Target $125
HCWC
Buy
Nektar data 'more robust' than Incyte's, says H.C. Wainwright
The failure of Incyte (INCY) and Merck's (MRK) Phase 3 study negatively impacted trading in Nektar Therapeutics (NKTR) shares on Friday, H.C. Wainwright analyst Debjit Chattopadhyay tells investors in a research note titled "Collateral Damage Not Surprising; Expecting ASCO-18 to Validate the Master T Cell Regulator Hypothesis." At this year's American Society of Clinical Oncology meeting, the analyst expects Nektar and partner Bristol-Myers Squibb (BMY) to unveil data from at least 40 advanced melanoma patients "supported by in-depth biomarker characterization to comprehensively ascertain the rationale of combining NKTR-214 with Opdivo." The rationale for combining NKTR-214 with Opdivo is "more robust" than epacadostat plus Keytruda, the analyst contends. Further, he believes data generated by the NKTR-214 plus Opdivo combination is "unambiguous." Chattopadhyay reiterates a Buy rating on Nektar shares with a $125 price target.
04/09/18
JEFF
04/09/18
DOWNGRADE
Target $4
JEFF
Hold
NewLink Genetics downgraded to Hold with $4 target at Jefferies
Jefferies analyst Biren Amin late Friday downgraded NewLink Genetics (NLNK) to Hold from Buy and cut his price target for the shares to $4 from $17. The stock closed Friday down 43%, or $3.12, to $4.20. The analyst does not see a scenario in which the company's IDO inhibitor can avoid the same fate as Incyte and Merck's epacadostat plus Keytruda failed study.
04/09/18
OPCO
04/09/18
NO CHANGE
Target $65
OPCO
Perform
Incyte price target lowered to $65 from $110 at Oppenheimer
Oppenheimer analyst Jay Olson lowered his price target for Incyte (INCY) to $65 from $110 following the update on the termination of ECHO-301 after epacadostat failed to show a PFS or OS benefit when combined with Merck's (MRK) Keytruda versus Keytruda alone. While the company plans to conduct subgroup analyses of ECHO-301 looking at various biomarkers such as PD-L1 expression and tumor mutational burden which may provide additional insights, the analyst sees no reason at this time to continue development of epacadostat as he considers it highly unlikely to demonstrate efficacy in other tumor types and/or combinations. Olson reiterates a Perform rating on Incyte's shares.
04/06/18
MZHO
04/06/18
NO CHANGE
Target $103
MZHO
Buy
Mizuho says failure of Incyte's epacadostat ups chances of Nektar takeover
Mizuho analyst Difei Yang raised her price target on Nektar Therapeutics (NKTR) to $103 from $89 after Incyte (INCY) announced this morning the failure of epacadostat in combination with Merck's (MRK) Keytruda in a phase 3 study in melanoma patients. Recent clinical data presented by Nektar reinforced her view of NKTR-214 as one of the most impressive combo agent for checkpoint inhibitors, said Yang, who believes that the failure of epacadostat raises the possibility of a takeout by Bristol-Myers (BMY) in the coming months. She maintains a Buy rating on Nektar shares, which are down 8.5% to $92.75 in afternoon trading.
MNLO Menlo Therapeutics
$35.22

-1 (-2.76%)

04/09/18
JEFF
04/09/18
DOWNGRADE
Target $20
JEFF
Hold
Menlo Therapeutics downgraded to Hold from Buy at Jefferies
Jefferies analyst David Steinberg downgraded Menlo Therapeutics to Hold and cut his price target for the shares to $20 from $41. The analyst is surprised that the Phase 2 clinical trial of serlopitant for the treatment of pruritus in adults and adolescents with a history of atopic dermatitis did not meet its primary or key secondary efficacy endpoints.
02/20/18
02/20/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Imax (IMAX) assumed with an Overweight at JPMorgan. 2. Gates Industrial (GTES) was initiated with an Outperform at RBC Capital and Credit Suisse, an Overweight at Morgan Stanley and KeyBanc, as well as a Buy at SunTrust, UBS, and Citi. 3. Menlo Therapeutics (MNLO) was initiated with an Outperform at JMP Securities, an Overweight at Piper Jaffray, and a Buy at Jefferies. 4. PlayAGS (AGS) was initiated with a Buy at SunTrust, BofA/Merrill, and Deutsche Bank. 5. PagSeguro Digital (PAGS) was initiated with a Neutral at JPMorgan, BofA/Merrill, UBS, and Deutsche Bank. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
04/09/18
PIPR
04/09/18
NO CHANGE
Target $48
PIPR
Overweight
Piper reiterates Overweight on Menlo Therapeutics after Phase II miss
Piper Jaffray analyst David Amsellem calls Menlo Therapeutics' serlopitant missing the primary and secondary endpoints in a Phase IIb study in patients with pruritis associated with atopic dermatitis as "big disappointment." The analyst, however, does not infer that the setback in atopic dermatitis "necessarily raises the risk" surrounding the prurigo nodularis Phase III trials. Prurigo nodularis is an altogether different condition, Amsellem tells investors in a research note. He believes last night's trial miss "should not call into question the overall viability of serlopitant as an anti-pruritic agent." Amsellem reiterates an Overweight rating on Menlo Therapeutics.
02/20/18
JMPS
02/20/18
INITIATION
Target $44
JMPS
Outperform
Menlo Therapeutics initiated with an Outperform at JMP Securities
JMP Securities analyst Donald Ellis started Menlo Therapeutics with an Outperform rating and $44 price target, nothing that he forecasts launches of treatments of prurigo nodularis, psoriasis and atopic dermatitis in early 2022. Ellis believes the U.S. pruritus market could easily exceed $1B, he tells investors.
TRPX Therapix Biosciences
$5.20

-0.3912 (-7.00%)

06/05/17
LTCO
06/05/17
INITIATION
Target $18
LTCO
Buy
Therapix Biosciences initiated with a Buy at Ladenburg
Laidlaw analyst Francois Brisebois initiated Therapix Biosciences with a Buy and an $18 price target saying lead candidate THXTS01, an orally available pill consisting of FDA approved dronabinol and palmitoylethanolamide for the treatment of symptoms related to Tourette Syndrome, has little competition and a large market opportunity.
BLUE Bluebird Bio
$162.70

-7.45 (-4.38%)

03/21/18
MSCO
03/21/18
NO CHANGE
Target $209
MSCO
Equal Weight
Bluebird Bio price target to $209 from $152 at Morgan Stanley
Morgan Stanley analyst Matthew Harrison raised his price target on Bluebird Bio (BLUE) to $209 from $152, stating that he now expects BCMA therapies to take 50% of the third line market by 2030 and noting that bb2121 has 50% market share there. The new assumptions increase his peak sales forecast to about $2.6B from about $1B, he pointed out. However, Harrison keeps an Equal Weight rating on Bluebird, stating that he would expect new data to be available at ASCO in June, but would also expect to see competitor data potentially from Celgene's (CELG) Juno, Gilead's (GILD) Kite, Johnson & Johnson's (JNJ) Nanjing Legend and others.
03/28/18
03/28/18
NO CHANGE

Bluebird Bio and Celegene to co-develop bb2121 anti-BMCA therapy
Bluebird Bio (BLUE) and Celgene (CELG) announced that the companies have entered into an agreement to co-develop and co-promote bb2121, an investigational anti-B-cell maturation antigen, or BCMA chimeric antigen receptor, or CAR, T cell therapy for the potential treatment of patients with relapsed/refractory multiple myeloma in the United States.The companies originally entered into a broad, global strategic research collaboration in 2013 to discover, develop and commercialize novel therapies in oncology, which included bb2121.
03/16/18
03/16/18
INITIATION

Bluebird Bio initiated with a Sell at Favus
ONCE Spark Therapeutics
$62.06

-1.19 (-1.88%)

02/21/18
CANT
02/21/18
NO CHANGE
Target $100
CANT
Overweight
Spark could have 'transformative year' in 2018, say Cantor Fitzgerald
Cantor Fitzgerald analyst Elemer Piros anticipates 2018 could become a "transformative year" for Spark Therapeutics with advancement of its hemophilia B program into Phase 3 development, greater clarity on Hemophilia A program in mid-2018, and the commercialization of Luxturna. The analyst lowered his price target for the shares to $100 from $105 following the company's Q4 results and reiterates an Overweight rating on the name.
03/08/18
FBCO
03/08/18
NO CHANGE
Target $75
FBCO
Outperform
Spark Therapeutics price target raised to $75 from $61 at Credit Suisse
Credit Suisse analyst Martin Auster raised his price target for Spark Therapeutics to $75 from $61 as he expects SPK-8011 to re-emerge as a competitive player in Hemophilia A gene therapy in 2018. The analyst reiterates an Outperform rating on the shares.
02/21/18
BERN
02/21/18
NO CHANGE
Target $60
BERN
Outperform
Spark Therapeutics price target lowered to $60 from $71 at Bernstein
Bernstein analyst Vincent Chen lowered his price target for Spark Therapeutics to $60 from $71 saying management's comments bode well for SPK-8011, but RPE65 model update takes down valuation. The analyst reiterates an Outperform rating on the shares.
BMRN BioMarin
$76.01

-2.69 (-3.42%)

03/23/18
RHCO
03/23/18
NO CHANGE
Target $130
RHCO
Buy
SunTrust sees FDA report on children's ACH treatment as positive for BioMarin
SunTrust analyst Edward Nash writes that his review of the latest FDA briefing document released ahead of Adcom meeting discussing the drug development for the treatment of children with achondroplasia may be a positive for Biomarin. Nash notes that the company is "established as a leader in the space" and its current trial design with top-line Phase 3 data expected in late 2019 may exceed FDA expectations. The analyst keeps his Buy rating and a $130 price target on BioMarin.
02/23/18
STFL
02/23/18
NO CHANGE
Target $102
STFL
Buy
Scrutiny of BioMarin's pegvaliase likely to increase, says Stifel
Stifel analyst Stephen Willey said BioMarin's better than consensus forecast for its FY18 revenue keeps him confident in the fundamentals of its base business, though the "increasingly measured" commentary from management around pegvaliase's regulatory path/labeling and subsequent launch trajectory reinforces his lack of confidence in his longer-term pegvaliase estimates. He contends that the May 25, 2018 PDUFA date for pegvaliase has become of "heightened importance for investors," Willey told investors earlier. He lowered his price target on BioMarin shares to $102 from $105, largely to reflect a shallower pegvaliase launch trajectory, but keeps a Buy rating on the stock.
02/23/18
BMOC
02/23/18
NO CHANGE
Target $125
BMOC
Outperform
BMO ups BioMarin target to $125, sees upside from guidance
BMO Capital analyst Ian Somaiya last night raised his price target for shares of BioMarin Pharmaceutical to $125 from $119 following the company's Q4 results. The analyst cites better total revenue guidance, higher pricing of pegvaliase, and the benefit of tax reform for the target bump. He believes BioMarin's 2018 guidance provides upside while its pipeline markets. The analyst kept an Outperform rating on the shares.
ABEO Abeona Therapeutics
$14.00

-0.35 (-2.44%)

01/23/18
01/23/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Abeona Therapeutics (ABEO) assumed with an Outperform at RBC Capital. 2. Jack Henry (JKHY) initiated with a Neutral at DA Davidson. 3. Woodward (WWD) re-initiated with a Market Perform at Barrington. 4. Navistar (NAV) initiated with a Neutral at Buckingham. 5. Global Blood Therapeutics (GBT) initiated with an Outperform at William Blair. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
01/30/18
JEFF
01/30/18
NO CHANGE
Target $28
JEFF
Buy
Jefferies views RMAT designation as 'underappreciated win' for Abeona
The Regenerative Medicine Advanced Therapy designation for EB-101 in recessive dystrophic epidermolysis bullosa is an "underappreciated win" for Abeona Therapeutics, Jefferies analyst Maury Raycroft tells investors in a research note. The analyst believes RMAT designation nearly ensures an "accelerated approval" path without need for formal post-approval confirmatory studies. He remains a buyer of Abeona shares with a $28 price target.
01/23/18
RBCM
01/23/18
INITIATION
Target $26
RBCM
Outperform
Abeona Therapeutics assumed with an Outperform at RBC Capital
RBC Capital analyst Kennen MacKay assumed Abeona Therapeutics coverage with an Outperform rating and a price target of $26, removing a Speculative Risk tag from the stock. MacKay says Abeona is an "emerging gene therapy player with a promising diversified pipeline of late- and early-stage assets targeting metabolic and dermatologic rare diseases", and he is positive on 2018 catalysts with anticipated data "validating datasets for MPS and/or RDEB".
NITE Nightstar Therapeutics
$11.70

-0.19 (-1.60%)

01/03/18
CHDN
01/03/18
INITIATION
Target $40
CHDN
Buy
Nightstar Therapeutics initiated with a Buy at Chardan
Chardan analyst Gbola Amusa started Nightstar Therapeutics with a Buy rating and $40 price target, citing the potential for its lead asset, NSR-REP1, for the treatment of choroideremia.
02/27/18
MZHO
02/27/18
INITIATION
Target $20
MZHO
Buy
Nightstar Therapeutics initiated with a Buy at Mizuho
Mizuho analyst Difei Yang started Nightstar Therapeutics with a Buy rating and $20 price target. The analyst believes the company, with a Phase III pivotal trial of NSR-REP1 starting in the first half of 2018, is leading the way in gene therapy for the treatment of choroideremia, a rare inherited retinal disease. Yang sees "strong potential" for NSR-REP1 with additional upside from the company's earlier-stage pipeline products.
10/23/17
10/23/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Ball Corp. (BLL) initiated with a Buy at UBS. 2. Deciphera (DCPH) was initiated with a Buy at Nomura Instinet, an Outperform at JMP Securities, and an Overweight at JPMorgan. 3. Nightstar Therapeutics (NITE) was initiated with an Outperform at Leerink, BMO Capital, and Wedbush, and a Buy at Jefferies. 4. Roku (ROKU) initiated with an Outperform at William Blair, a Perform at Oppenheimer, a Sector Perform at RBC Capital, an Equal Weight at Morgan Stanley, and a Neutral at Citi. 5. Tableau (DATA) initiated with a Buy at Needham. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
VYGR Voyager Therapeutics
$17.37

-0.76 (-4.19%)

03/12/18
WEDB
03/12/18
DOWNGRADE
WEDB
Neutral
Voyager Therapeutics downgraded to Neutral from Outperform at Wedbush
03/12/18
03/12/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Ranger Energy (RNGR) downgraded to Market Perform from Outperform at Wells Fargo with analyst Judson Bailey saying the growth and margin improvement story he originally forecasted has come in "well below expectations along with disappointing free cash flow." 2. Voyager Therapeutics (VYGR) was downgraded to In Line from Outperform at Evercore ISI and to Neutral from Outperform at Wedbush. 3. HubSpot (HUBS) downgraded to In Line from Outperform at Evercore ISI with analyst Kirk Materne saying he is taking a "few chips off the table" and sees more balanced risk/reward at current levels. 4. XL Group (XL) downgraded to Market Perform from Outperform at JMP Securities with analyst Matthew Carletti saying that he sees low odds of a superior offer following the company's announcement of a deal to be acquired by AXA (AXAHY) for $57.60 per share in cash. 5. Blackbaud (BLKB) downgraded to Underperform from In Line at Evercore ISI with analyst Kirk Materne saying Blackbaud's valuation reflects the current cloud transition and lower tax rate and is full relative to the company's TTM organic growth rate. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/12/18
03/12/18
DOWNGRADE
Target $29

Neutral
Voyager downgraded to Neutral after Parkinson's drug data at Wedbush
As previously reported, Wedbush analyst David Nierengarten downgraded Voyager Therapeutics to Neutral from Outperform, stating that data from its Phase 1 study of VY-AADC were "on the whole positive," though inconsistencies in dose response and variability in L-dopa usage "complicates" the story and raise questions on activity that could complicate the upcoming Phase 2/3 trial. However, Nierengarten raised his price target on Voyager shares to $29 from $22.
MTG MGIC Investment
$12.82

-0.17 (-1.31%)

03/12/18
WELS
03/12/18
NO CHANGE
WELS
Mortgage Insurers sliding on fears about Freddie pilot, says Wells Fargo
After Dowling Research said Freddie Mac (FMCC) has introduced an alternative for securing mortgage insurance as a pilot program with Arch Capital (ACGL) that has pricing "solidly below" published mortgage insurer lender-paid singles rate cards, Wells Fargo analyst Sean Dargan noted that Essent Group (ESNT), MGIC Investment (MTG) and Radian Group (RDN) are down 8%-11% in reaction to fears that Arch will gain meaningful share in the Freddie business. While awaiting more information from both Arch and Freddie Mac, Dargan said that Essent, given its Bermuda reinsurance structure, would be better positioned to replicate the Arch model than would MGIC or Radian. Near midday, Essent is down 8%, MGIC is down 9% and Radian is down 11%.
03/14/18
MACQ
03/14/18
INITIATION
MACQ
Outperform
MGIC Investment initiated with an Outperform at Macquarie
Macquarie initiated MGIC Investment with an Outperform and $17 price target.
03/13/18
RILY
03/13/18
NO CHANGE
RILY
B. Riley FBR says buy MGIC, NMI following yesterday's weakness
B. Riley FBR analyst Randy Binner recommends buying shares of MGIC Investment (MTG) and NMI Holdings (NMIH) following yesterday's selloff on the Freddie Mac/Arch headlines. While still a proposal, the new structure would only be marginally dilutive to earnings if implemented, Binner tells investors in a research note.
03/13/18
DBAB
03/13/18
NO CHANGE
DBAB
Private Mortgage Insurer selloff yesterday overdone, says Deutsche Bank
Shares of Private Mortgage Insurers were down roughly 10% yesterday following news that Freddie Mac (FMCC) and private MI Arch had initiated a structure whereby a panel of reinsurers will provide the necessary credit risk enhancement for a portion of low down-payment mortgages otherwise met by traditional mortgage insurance, Deutsche Bank analyst Phil Stefano tells investors in a research note. The analyst recommends buying Essent Group (ESNT), MGIC Investment (MTG), NMI Holdings (NMIH) and Radian Group (RDN) following yesterday's weakness. Clients have relayed from reports the potential for a 10%-30% decline in Singles pricing, the analyst says. He notes this business makes up roughly 15%-20% of new business being written today. Assuming a 20% price cut on 20% of the business combined with the uncertainties underlying the new structure, Stefano would have anticipated a "muted high-single-digit reaction to the stocks." He feels the selloff yesterday in the Private Mortgage Insurers is overdone.
RDN Radian Group
$19.14

-0.2 (-1.03%)

03/14/18
MACQ
03/14/18
INITIATION
MACQ
Neutral
Radian Group initiated with a Neutral at Macquarie
03/15/18
03/15/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Radian Group (RDN) initiated with a Neutral at Macquarie. 2. Cheniere Energy (LNG) initiated with a Buy at BofA/Merrill. 3. Avid Bioservices (CDMO) initiated with an Outperform at Wells Fargo. 4. Quintana Energy Services (QES) initiated with an Overweight at Capital One. 5. II-VI (IIVI) initiated with a Buy at DA Davidson. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
ESNT Essent Group
$42.07

-0.82 (-1.91%)

02/12/18
ZELM
02/12/18
UPGRADE
ZELM
Buy
Essent Group upgraded to Buy from Hold at Zelman
03/14/18
MACQ
03/14/18
INITIATION
Target $62
MACQ
Outperform
Essent Group initiated with an Outperform at Macquarie
Macquarie initiated Essent Group with an Outperform and $62 price target.

TODAY'S FREE FLY STORIES

TWX

Time Warner

$96.23

-0.34 (-0.35%)

, CMCSA

Comcast

$33.21

-0.28 (-0.84%)

17:04
04/22/18
04/22
17:04
04/22/18
17:04
Hot Stocks
Box Office Battle: 'A Quiet Place' reclaims first place with $22M »

Paramount's (VIAB)…

TWX

Time Warner

$96.23

-0.34 (-0.35%)

CMCSA

Comcast

$33.21

-0.28 (-0.84%)

CMCSK

Comcast

SNE

Sony

$49.76

0.03 (0.06%)

FOX

21st Century Fox

$36.21

-0.46 (-1.25%)

FOXA

21st Century Fox

$36.69

-0.51 (-1.37%)

LGF.A

Lionsgate

$25.76

-0.44 (-1.68%)

DIS

Disney

$100.24

-0.64 (-0.63%)

VIAB

Viacom

$30.65

-0.1 (-0.33%)

VIA

Viacom

$35.35

-0.25 (-0.70%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 25

    Apr

  • 25

    Apr

  • 25

    Apr

  • 08

    May

  • 09

    May

  • 09

    May

BAC

Bank of America

$30.26

0.06 (0.20%)

, WFC

Wells Fargo

$52.57

1.02 (1.98%)

16:40
04/22/18
04/22
16:40
04/22/18
16:40
Periodicals
Big banks push mortgage apps, websites as home lending slows, Reuters reports »

Big U.S. banks are racing…

BAC

Bank of America

$30.26

0.06 (0.20%)

WFC

Wells Fargo

$52.57

1.02 (1.98%)

JPM

JPMorgan

$111.47

-0.26 (-0.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 25

    Apr

  • 15

    May

  • 16

    May

  • 30

    May

  • 13

    Jul

  • 12

    Oct

AMZN

Amazon.com

$1,527.39

-29.57 (-1.90%)

16:34
04/22/18
04/22
16:34
04/22/18
16:34
Periodicals
Amazon to broaden offering in groceries in India, Reuters says »

Amazon expects groceries…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

F

Ford

$10.82

-0.14 (-1.28%)

, WPP

WPP

$80.16

-1.21 (-1.49%)

16:27
04/22/18
04/22
16:27
04/22/18
16:27
Periodicals
Ford to take bids on some advertising managed by WPP, Reuters reports »

Ford (F) said it will…

F

Ford

$10.82

-0.14 (-1.28%)

WPP

WPP

$80.16

-1.21 (-1.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

FB

Facebook

$166.29

-1.82 (-1.08%)

16:23
04/22/18
04/22
16:23
04/22/18
16:23
Periodicals
Facebook sets lobbying record, Axios reports »

Facebook spent $3.3M on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

AKRX

Akorn

$19.68

0.31 (1.60%)

, FSNUY

Fresenius SE

16:19
04/22/18
04/22
16:19
04/22/18
16:19
Hot Stocks
Akorn responds to Fresenius decision to terminate merger agreement »

Akorn (AKRX) issued a…

AKRX

Akorn

$19.68

0.31 (1.60%)

FSNUY

Fresenius SE

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INFY

Infosys

$17.38

0.21 (1.22%)

15:34
04/22/18
04/22
15:34
04/22/18
15:34
Conference/Events
Infosys to host analyst meeting »

Analyst meeting to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKRX

Akorn

$19.68

0.31 (1.60%)

, FSNUY

Fresenius SE

14:08
04/22/18
04/22
14:08
04/22/18
14:08
Hot Stocks
Fresenius terminates merger agreement with Akorn over data breaches »

Fresenius (FSNUY) decided…

AKRX

Akorn

$19.68

0.31 (1.60%)

FSNUY

Fresenius SE

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LEVB

Level Brands

$5.15

0.25 (5.10%)

12:20
04/22/18
04/22
12:20
04/22/18
12:20
Conference/Events
Level Brands CEO Sumichrast interview to air on The RedChip Money Report »

Marty Sumichrast,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Apr

LEVB

Level Brands

$5.15

0.25 (5.10%)

04:55
04/22/18
04/22
04:55
04/22/18
04:55
Conference/Events
Level Brands CEO Sumichrast interview to air on The RedChip Money Report »

Marty Sumichrast,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Apr

04:55
04/22/18
04/22
04:55
04/22/18
04:55
Conference/Events
International Monetary Fund & World Bank Group to co-host an annual meeting »

2018 Spring Meeting will…

CGNT

Cogentix Medical

$3.84

-0.005 (-0.13%)

19:21
04/21/18
04/21
19:21
04/21/18
19:21
Hot Stocks
Laborie Medical announces completion of tender offer for Cogentix Medical »

Laborie Medical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSG

The Stars Group

$29.35

0.4 (1.38%)

, SKYAY

Sky

18:31
04/21/18
04/21
18:31
04/21/18
18:31
Hot Stocks
The Stars Group to acquire Sky Betting & Gaming for $4.7B »

The Stars Group (TSG)…

TSG

The Stars Group

$29.35

0.4 (1.38%)

SKYAY

Sky

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LUV

Southwest

$54.76

-0.02 (-0.04%)

18:22
04/21/18
04/21
18:22
04/21/18
18:22
Hot Stocks
Southwest responds to Emergency Airworthiness Directive »

Southwest Airlines said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 10

    May

TPR

Tapestry

$53.03

-0.255 (-0.48%)

16:17
04/21/18
04/21
16:17
04/21/18
16:17
Periodicals
Tapestry could see more stock gains, Barron's says »

In a follow-up story,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 23

    May

DAL

Delta Air Lines

$55.40

0.34 (0.62%)

, GM

General Motors

$37.61

-0.16 (-0.42%)

16:05
04/21/18
04/21
16:05
04/21/18
16:05
Periodicals
Delta, GM look cheap, with growth potential, Barron's says »

While a solid start to…

DAL

Delta Air Lines

$55.40

0.34 (0.62%)

GM

General Motors

$37.61

-0.16 (-0.42%)

GT

Goodyear Tire

$27.00

0.06 (0.22%)

LNC

Lincoln National

$71.59

-0.04 (-0.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 26

    Apr

  • 03

    May

  • 30

    May

  • 20

    Jun

  • 26

    Jun

  • 29

    Jun

GIS

General Mills

$43.41

-0.61 (-1.39%)

15:57
04/21/18
04/21
15:57
04/21/18
15:57
Periodicals
General Mills shares fall to 'bargain territory,' Barron's says »

General Mills has fallen…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CCL

Carnival

$65.88

0.82 (1.26%)

, RCL

Royal Caribbean

$119.11

1.18 (1.00%)

15:51
04/21/18
04/21
15:51
04/21/18
15:51
Periodicals
Cruise operators can offer 'nice' yields, solid dividend growth, Barron's says »

Cruise operators, like…

CCL

Carnival

$65.88

0.82 (1.26%)

RCL

Royal Caribbean

$119.11

1.18 (1.00%)

NCLH

Norwegian Cruise Line

$55.65

0.71 (1.29%)

DIS

Disney

$100.24

-0.64 (-0.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    May

  • 08

    May

GOOG

Alphabet

$1,072.73

-15.18 (-1.40%)

, GOOGL

Alphabet Class A

$1,076.64

-12.83 (-1.18%)

15:42
04/21/18
04/21
15:42
04/21/18
15:42
Periodicals
Tech giants may make own custom chips to get edge on one another, Barron's says »

There has been a tension…

GOOG

Alphabet

$1,072.73

-15.18 (-1.40%)

GOOGL

Alphabet Class A

$1,076.64

-12.83 (-1.18%)

AMZN

Amazon.com

$1,527.39

-29.57 (-1.90%)

FB

Facebook

$166.29

-1.82 (-1.08%)

AAPL

Apple

$165.71

-7.08 (-4.10%)

MSFT

Microsoft

$95.01

-1.1 (-1.14%)

BIDU

Baidu

$232.38

-4.73 (-1.99%)

BABA

Alibaba

$179.07

-2.14 (-1.18%)

INTC

Intel

$51.53

-0.68 (-1.30%)

NVDA

Nvidia

$228.74

-0.21 (-0.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 23

    Apr

  • 25

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 01

    May

  • 04

    May

  • 10

    May

EPD

Enterprise Products

$26.60

-0.03 (-0.11%)

, MMP

Magellan Midstream

$65.16

-0.755 (-1.15%)

15:32
04/21/18
04/21
15:32
04/21/18
15:32
Periodicals
MPL valuations look cheap, Barron's says »

Master limited…

EPD

Enterprise Products

$26.60

-0.03 (-0.11%)

MMP

Magellan Midstream

$65.16

-0.755 (-1.15%)

MPLX

MPLX

PAA

Plains All American

$24.68

0.42 (1.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

  • 03

    May

  • 08

    May

AMZN

Amazon.com

$1,527.39

-29.57 (-1.90%)

, TWX

Time Warner

$96.23

-0.34 (-0.35%)

08:34
04/21/18
04/21
08:34
04/21/18
08:34
Periodicals
Trump's tweets politicize U.S. markets, Barron's says »

With President Donald…

AMZN

Amazon.com

$1,527.39

-29.57 (-1.90%)

TWX

Time Warner

$96.23

-0.34 (-0.35%)

T

AT&T

$34.67

-0.15 (-0.43%)

MYL

Mylan

$40.73

-0.08 (-0.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 25

    Apr

  • 26

    Apr

  • 27

    Apr

  • 18

    May

  • 13

    Nov

FB

Facebook

$166.29

-1.82 (-1.08%)

, AAPL

Apple

$165.71

-7.08 (-4.10%)

08:15
04/21/18
04/21
08:15
04/21/18
08:15
Periodicals
Facebook, Apple embody new tech divide, Barron's says »

For several years now,…

FB

Facebook

$166.29

-1.82 (-1.08%)

AAPL

Apple

$165.71

-7.08 (-4.10%)

AMZN

Amazon.com

$1,527.39

-29.57 (-1.90%)

NFLX

Netflix

$327.57

-5.12 (-1.54%)

GOOG

Alphabet

$1,072.73

-15.18 (-1.40%)

GOOGL

Alphabet Class A

$1,076.64

-12.83 (-1.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 23

    Apr

  • 25

    Apr

  • 26

    Apr

  • 01

    May

AMZN

Amazon.com

$1,527.39

-29.57 (-1.90%)

, ACIA

Acacia Communications

$27.54

1.04 (3.92%)

08:00
04/21/18
04/21
08:00
04/21/18
08:00
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AMZN

Amazon.com

$1,527.39

-29.57 (-1.90%)

ACIA

Acacia Communications

$27.54

1.04 (3.92%)

OCLR

Oclaro

$8.27

0.08 (0.98%)

NOK

Nokia

$5.96

0.125 (2.14%)

NPTN

NeoPhotonics

$6.05

-0.01 (-0.17%)

LITE

Lumentum

$58.90

-1.05 (-1.75%)

FNSR

Finisar

$15.43

0.045 (0.29%)

MSFT

Microsoft

$95.01

-1.1 (-1.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 02

    May

  • 03

    May

  • 09

    May

  • 23

    May

  • 29

    May

  • 12

    Jun

  • 26

    Jun

04:55
04/21/18
04/21
04:55
04/21/18
04:55
Conference/Events
International Monetary Fund & World Bank Group to co-host an annual meeting »

2018 Spring Meeting will…

SPX

S&P 500

, SPY

SPDR S&P 500 ETF Trust

$266.66

-2.18 (-0.81%)

18:08
04/20/18
04/20
18:08
04/20/18
18:08
Periodicals
North Korea to suspend nuclear and ICBM tests, Bloomberg reports »

North Korea also plans to…

SPX

S&P 500

SPY

SPDR S&P 500 ETF Trust

$266.66

-2.18 (-0.81%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.